References
- Tibblin G. Introduction to the epidemiology of dyspepsia. Scand J Gastroenterol 1985; 20: 29–33, Suppl 109
- Knill-Jones RP. Geographical differences in the prevalence of dyspepsia. Scand J Gastroenterol 1991; 26: 17–24, Suppl 182
- Talley NJ, Zinsmeister AR, Schelck CD, Melton JL, III. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992; 102: 1259–68
- Vartiainen E, Jousilahti P, Tamminen M, Korhonen HJ, Tuomilehto J, Sundvall J, et al. FINRISKI'92. Helsinki: Kan-santerveyslaitoksen julkaisuja 1993; B9: 1993
- Heikkinen M, Pikkarainen P, Takala J, Julkunen R. General practitioner's approach to dyspepsia. Scand J Gastroenterol 1996; 31: 648–53
- Jones R, Lydeard S. Prevalence of symptoms of dyspepsia in the community. Br Med J 1989; 298: 30–2
- Colin-Jones DG, Bloom B, Bodemar G, Crean G, Freston J, Gugler R, et al. Management of dyspepsia: report of a working party. Lancet 1988; 334: 576–9
- Stakes Tautiluokitus ICD-10: (International Statistical Classification of Diseases and Related Health Problems. Volume. 1). Stakes 1995; 3
- Anonymous. H2 antagonists for ‘indigestion’. Pharm J 1996; 256: 85
- Heatley RV, Rathbone BJ. Dyspepsia: a dilemma for doctors?. Lancet 1987; 33: 779–81
- Fallsberg M, Holme-Hansen E. Handboksmedicin: danske og europaeiske perspectiver. Sundhetsstyrelsen, Laegemiddelafdelingen, Copenhagen 1995
- Andersen M, Schou JS. Safety implications of the over-the-counter availability of H2-antagonists. Drug Safety 1993; 8: 179–85
- Klaukka T, Martikainen J, Kalimo E. Drug utilization in Finland 1964-1987. Publications of the Social Insurance Institution M, Helsinki, 71: 1990
- McCarthy DM. Sucralfate. N Engl J Med 1991; 325: 1017–25
- Martyn CN, Barker DJP, Osmond C, Harris EC, Edwardson JA, Lacey RF. Georaphical relation between Alzheimer's disease and aluminium in drinking water. Lancet 1989; 335: 59–62
- Fleming LW, Prescott A, Stewart WK, Cargill RW. Bioavailability of aluminium. Lancet 1989; 335: 433
- Sontag SJ. The medical management of reflux esophagitis. Gastroenterol Clin North Am 1990; 19: 683–712
- Feldman M. Comparison of the effects of over-the-counter famotidine and calcium carbonate antacid on postprandial gastric acid. JAMA 1996; 275: 1428–31
- Feldman M. Pros and cons of over-the-counter availability of histamine2-receptor antagonists. Arch Intern Med 1993; 153: 2415–24
- Hunt RH. Habit, prejudice, power and politics: issues in the conversation of H2-receptor antagonists to over-the-counter use. Can Med Assoc J 1996; 154: 49–53
- Douds AC, Maxwell JD. Over the counter H2 receptor antagonists serve only as expensive antacids. Br Med J 1994; 309: 1156
- Gossel TA. Implication of the reclassification of drugs from prescription-only to over-the-counter status. Clin Ther 1991; 13: 200–15
- Bond CM, Grimshaw JM. Multi-disciplinary guideline development: a case study from community pharmacy. Health Bull 1995; 53: 26–33
- Hemminki E, Herxheimer A. Should drug information be an integral part of health care?. J R Coll Physicians Lond 1996; 30: 104–6